Ana Olívia Fonseca1, Arthur A Berberian2, Carolina de Meneses-Gaya3, Ary Gadelha3, Marcella de O Vicente3, Keith H Nuechterlein4, Rodrigo A Bressan3, Acioly L T Lacerda3. 1. Universiedade Federal de Sao Paulo (Unifesp), Department of Psychiatry, Interdisciplinary Lab of Clinical Neurosciences (LiNC), and Schizophrenia Program (PROESQ), Brazil. Electronic address: anaoliviaf@hotmail.com. 2. Universiedade Federal de Sao Paulo (Unifesp), Department of Psychiatry, Interdisciplinary Lab of Clinical Neurosciences (LiNC), and Schizophrenia Program (PROESQ), Brazil; Centro Universitário FIEO, Strict Sensu Educational Psychology Program, 300 UCLA Medical Plaza, Room 2240, Los Angeles, CA 90095, USA. 3. Universiedade Federal de Sao Paulo (Unifesp), Department of Psychiatry, Interdisciplinary Lab of Clinical Neurosciences (LiNC), and Schizophrenia Program (PROESQ), Brazil. 4. UCLA, Department of Psychiatry and Biobehavioral Sciences , 300 UCLA Medical Plaza, Room 2240, Los Angeles, CA 90095, USA; UCLA, Department Psychology, 300 UCLA Medical Plaza, Room 2240, Los Angeles, CA 90095, USA.
Abstract
OBJECTIVE: Translate, adapt, and validate the MATRICS Consensus Cognitive Battery (MCCB) in Brazil. METHOD: The present study followed three steps: 1) translation to Portuguese, cultural adaptation, and back translation to English; 2) completion of a pilot study (N=30) conducted with the purpose of assessing whether the general comprehension of the items was clear and all participants adequately responded to the battery; 3) completion of a Reliability and Validation Study of the Brazilian version of the MCCB with 99 individuals with schizophrenia and 99 healthy subjects. All participants were administered the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) and patients were also rated on the Global Assessment of Functioning (GAF) Scale and the Positive and Negative Symptoms Scale (PANSS). RESULTS: The results showed adequate to high levels of baseline and 4-week retest reliability, except the MSCEIT-ME; adequate internal consistency for the MSCEIT-ME for the total sample and patients group, and moderate Alpha for the health control sample; as well as evidence of convergent validity and sensitivity to differentiate performance between the groups. All the 10 MCCB measures showed the lowest learning effects. CONCLUSION: Overall the Brazilian version of the MCCB showed similar results to the original North American version. Our findings provides reassurance that the MCCB is a reliable and valid measure of cognition across different countries and cultures, which is especially important to the ongoing work in attempting to discover cognition-enhancing drugs and the effects of cognitive interventions for the treatment of schizophrenia.
OBJECTIVE: Translate, adapt, and validate the MATRICS Consensus Cognitive Battery (MCCB) in Brazil. METHOD: The present study followed three steps: 1) translation to Portuguese, cultural adaptation, and back translation to English; 2) completion of a pilot study (N=30) conducted with the purpose of assessing whether the general comprehension of the items was clear and all participants adequately responded to the battery; 3) completion of a Reliability and Validation Study of the Brazilian version of the MCCB with 99 individuals with schizophrenia and 99 healthy subjects. All participants were administered the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) and patients were also rated on the Global Assessment of Functioning (GAF) Scale and the Positive and Negative Symptoms Scale (PANSS). RESULTS: The results showed adequate to high levels of baseline and 4-week retest reliability, except the MSCEIT-ME; adequate internal consistency for the MSCEIT-ME for the total sample and patients group, and moderate Alpha for the health control sample; as well as evidence of convergent validity and sensitivity to differentiate performance between the groups. All the 10 MCCB measures showed the lowest learning effects. CONCLUSION: Overall the Brazilian version of the MCCB showed similar results to the original North American version. Our findings provides reassurance that the MCCB is a reliable and valid measure of cognition across different countries and cultures, which is especially important to the ongoing work in attempting to discover cognition-enhancing drugs and the effects of cognitive interventions for the treatment of schizophrenia.
Authors: Larissa C Martini; Jair B Barbosa Neto; Beatriz Petreche; Ana O Fonseca; Fernanda V Dos Santos; Lílian Magalhães; Alessandra G Marques; Camila Soares; Quirino Cordeiro; Cecília Attux; Rodrigo A Bressan Journal: Braz J Psychiatry Date: 2017-08-21 Impact factor: 2.697
Authors: J S Gomes; A P Trevizol; D V Ducos; A Gadelha; B B Ortiz; A O Fonseca; H T Akiba; C C Azevedo; L S P Guimaraes; P Shiozawa; Q Cordeiro; A Lacerda; A M Dias Journal: Schizophr Res Cogn Date: 2018-02-20